Centessa Pharmaceuticals plc (NASDAQ:CNTA) Short Interest Up 37.3% in November

Centessa Pharmaceuticals plc (NASDAQ:CNTA) was the recipient of a large increase in short interest during the month of November. As of November 30th, there was short interest totalling 3,350,000 shares, an increase of 37.3% from the November 15th total of 2,440,000 shares. Approximately 3.8% of the shares of the company are sold short. Based on an average daily volume of 680,400 shares, the days-to-cover ratio is currently 4.9 days.

Insider Buying and Selling

In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 11,742 shares of the company’s stock in a transaction that occurred on Friday, October 25th. The stock was sold at an average price of $15.38, for a total value of $180,591.96. Following the completion of the transaction, the insider now owns 183,266 shares of the company’s stock, valued at $2,818,631.08. This represents a 6.02 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Saurabh Saha sold 87,496 shares of the firm’s stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $18.46, for a total value of $1,615,176.16. Following the completion of the sale, the chief executive officer now owns 575,661 shares of the company’s stock, valued at $10,626,702.06. This represents a 13.19 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 262,624 shares of company stock valued at $4,497,698. Company insiders own 11.59% of the company’s stock.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. grew its holdings in Centessa Pharmaceuticals by 47.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock worth $40,000 after purchasing an additional 826 shares during the period. Atria Investments Inc raised its position in shares of Centessa Pharmaceuticals by 7.0% during the third quarter. Atria Investments Inc now owns 17,134 shares of the company’s stock worth $274,000 after purchasing an additional 1,116 shares during the period. GAMMA Investing LLC increased its stake in Centessa Pharmaceuticals by 103.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock valued at $48,000 after purchasing an additional 1,509 shares in the last quarter. Quarry LP increased its position in shares of Centessa Pharmaceuticals by 47.8% during the second quarter. Quarry LP now owns 9,608 shares of the company’s stock worth $87,000 after acquiring an additional 3,108 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of Centessa Pharmaceuticals by 99.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,593 shares of the company’s stock worth $217,000 after acquiring an additional 6,785 shares during the last quarter. Institutional investors and hedge funds own 82.01% of the company’s stock.

Centessa Pharmaceuticals Price Performance

Shares of Centessa Pharmaceuticals stock traded down $0.30 on Friday, reaching $16.57. 873,593 shares of the stock were exchanged, compared to its average volume of 429,306. The firm’s 50 day moving average is $16.49 and its 200-day moving average is $13.21. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. Centessa Pharmaceuticals has a one year low of $6.65 and a one year high of $18.97. The firm has a market cap of $2.18 billion, a PE ratio of -10.83 and a beta of 1.52.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.05. As a group, analysts anticipate that Centessa Pharmaceuticals will post -1.6 EPS for the current fiscal year.

Wall Street Analyst Weigh In

CNTA has been the topic of several recent analyst reports. Guggenheim boosted their price objective on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a research note on Friday, November 15th. B. Riley started coverage on shares of Centessa Pharmaceuticals in a research note on Thursday, September 19th. They set a “buy” rating and a $33.00 price target on the stock. Morgan Stanley raised Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $11.00 to $26.00 in a research note on Thursday, September 19th. BMO Capital Markets lifted their price objective on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an “outperform” rating in a research report on Monday, September 16th. Finally, Jefferies Financial Group lifted their target price on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, September 11th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Centessa Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $25.83.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.